多肽类药物微球注射制剂的研究进展  

Progress in Injectable Microsphere Formulations of Peptide Drugs

作　　者：徐晓寒[1] 吴闻哲[1] 

机构地区：[1]中国医药工业研究总院药物制剂国家工程研究中心,上海201203

出　　处：《中国医药工业杂志》2014年第10期985-990,共6页Chinese Journal of Pharmaceuticals

摘　　要：由于载体材料、制备工艺的限制及大分子药物本身的特殊性质,目前上市的大分子微球注射制剂多集中于相对分子量小于1 500的多肽类,鲜有分子量较大、空间结构复杂的蛋白类药物。综述了近年来用作多肽类药物注射微球的新型载体材料、制备方法及该类药物的上市情况。Because of the limitation of the materials, complicated preparation methods and the intrinsic unstable property of biological macromolecules, the marketed injectable microsphere formulations are more concentrated in peptide drugs with molecular weight no more than 1 500, while few protein drugs with larger molecular weight and more complicated structure can be found currently in the market. This paper reviews the recent progress of long-acting injectable microspheres of peptide and protein drugs, including the applications of novel materials and preparation methods as well as the market situation.

关 键 词：生物大分子 注射微球 新材料 制备方法 综述 

分 类 号：R944.9[医药卫生—药剂学]